Solorank
Login

Cached score snapshot

US.DXCM · Dexcom

110分制 58.6/110；5D動能v2 4/50；排序分 62.6/160

Back to ranking Open volume snapshot
Ranking score 62.6/160
Main score 58.6/110
5D momentum v2 4/50
Rank #103
Setup grade F 30.4

Score breakdown

觀望

Medium twelvedata

Score and price trend

F 30.4 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 07-08 09-21 10-14 10-29 11-11 $67.21$85.93$104.64 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.443 · anchors 120 +0.76% -1.66% / +3.17% 62.5% 2.5% Actual +0.71% · vs median -0.05% · inside 25-75 band
30D observation +7.73% -2.24% / +12.60% 70% 12.5% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.76% -1.19% / +2.69% 61.9% 3.8% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-07-08 → 2026-11-11 · 206 archived points · 2 Improving turn signal · 5 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 62.6
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 58.6/110 (觀望)
5D momentum v2 4/50 (弱)
Score with momentum v2 62.6/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 86.9565
ma50 85.7822
close 86.29
prevClose 86.64
avgVolume20 4120784
volumeRatio 0.83
changePercent -0.4

Metrics snapshot

close 86.29
volume 3409070
changePercent -0.4

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 58.6/110
Main rating 觀望
5D momentum v2 4/50
Score with momentum v2 62.6/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.6/5 · 優秀
Dimension score 4.6/5
Dimension grade 優秀

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0.75
roePoints 0.75
debtPoints 0.5
marginPoints 0.6
turnoverUsdM 294.1687
volumePoints 0.5
revenuePoints 0.6
dividendPoints 0
marketCapPoints 0.5

資金流 — 12.4/20 · 一般
Dimension score 12.4/20
Dimension grade 一般

Sub-items

cmfPoints 1.6
mfiPoints 4
obvPoints 4
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.DXCM
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 9.4/15 · 一般
Dimension score 9.4/15
Dimension grade 一般

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 16.04

trend

score 2.4

details

qqq

ma20 724.5445
ma50 714.931
name QQQ
close 739.77
points 2

spy

ma20 765.0635
ma50 762.7414
name SPY
close 762.63
points 0.4
source twelvedata+fred
atrPct 2.4341
atrPoints 3
cciPoints 1.6
vixPoints 2.4
marketTrendPoints 2.4

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 7.4/10 · 良好
Dimension score 7.4/10
Dimension grade 良好

Sub-items

position

score 1.6

details

atrPct 2.4341
turnoverUsdM 294.1687
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DXCM
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 82.0892

strength_details

ma_score 2
atr_score 2
rsi_score 2
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.9
take_profit_price 90.7463
target_multiplier 1.9
technical_strength 1.68
take_profit_percent 5.2
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.8682
diversificationPoints 2

技術信號 — 18.8/30 · 一般
Dimension score 18.8/30
Dimension grade 一般

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 2.4
vcpPoints 1.5
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1.5
vcp_reason 跌縮量(近10日5日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N

vcp_metrics

up_days 4
vol_ref 4092880
down_days 5
vcp_ready false
above_ma50 true
avg_vol_10 4605870
avg_vol_20 4057910
avg_vol_30 4092880
range_pct_10 0.0597
range_pct_20 0.1165
range_pct_30 0.1194
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok true
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 1.1253
dist_to_20d_high 0.0655
down_shrink_days 5
breakout_level_20d 92.34
vcp_breakout_confirm false
contraction_ratio_10_30 0.5
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 2.4
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.6

sentimentData

raw {"id":142389564,"url":"https://finnhub.io/api/news?id=ab4f9e99bbbeb3352d6984d2da00ffaa897b44bbcdf67afb376dbf86253e3dd1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...","category":"company","datetime":1790295609,"headline":"DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow"}, {"id":142370918,"url":"https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...","category":"company","datetime":1790224168,"headline":"Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"}, {"id":142366064,"url":"https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...","category":"company","datetime":1790201622,"headline":"DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"}, {"id":142025511,"url":"https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"DXCM","summary":"DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...","category":"company","datetime":1788952625,"headline":"DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"}, {"id":141953963,"url":"https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.","category":"company","datetime":1788871017,"headline":"DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"}, {"id":141425987,"url":"https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...","category":"company","datetime":1788506376,"headline":"DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"}, {"id":141403938,"url":"https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.","category":"company","datetime":1788463638,"headline":"Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"}, {"id":141364461,"url":"https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.","category":"company","datetime":1788275900,"headline":"3 Reasons DXCM Has Explosive Upside Potential"}
raw_source {"id":142498271,"url":"https://finnhub.io/api/news?id=c8a3883a0d743ae06ec3b632acdcbfbf365a4abeaa0485104c7b26b8a525f462","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.","category":"company","datetime":1790690760,"headline":"Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal"}, {"id":142471977,"url":"https://finnhub.io/api/news?id=9a9e8c90864916b48c6ae5ca4c5a7b7e7529ccc85f497dba335c6b61d6fd5ef0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.","category":"company","datetime":1790627760,"headline":"This Stock Could Be the Big Winner Out of Oura’s IPO"}, {"id":142467285,"url":"https://finnhub.io/api/news?id=3769358d3e460e01434eddeed80016e677e5f20103e739e42ecba5af01f9f33d","image":"https://cdn.benzinga.com/files/images/story/2026/09/28/Stock-market-chart--representative-image.jpg?width=2048&height=1536","source":"Benzinga","related":"DXCM","summary":"Market Overview\n\n\n\nStocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the","category":"company","datetime":1790585196,"headline":"The Insider Report: The Leaders Have Taken Off"}, {"id":142460907,"url":"https://finnhub.io/api/news?id=a57368bc532321048255f0eef4d920cdc87da7fdf7b0ffdeef89f459559e6839","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.","category":"company","datetime":1790578800,"headline":"Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets"}, {"id":142460906,"url":"https://finnhub.io/api/news?id=d7a5888e163f7e34cadd3d2f283f60b4d3498bf33975189d23da7e00b1acf7e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"MILAN, September 28, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its \"Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology\" in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk.","category":"company","datetime":1790575200,"headline":"Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care"}, {"id":142467762,"url":"https://finnhub.io/api/news?id=b6dca09324250ed8938c3bd363d9f85be70e0d34f6d15f85c4c20ae05dfa6950","image":"","source":"Benzinga","related":"DXCM","summary":"New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s commitment to advancing","category":"company","datetime":1790565474,"headline":"Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries"}, {"id":142421217,"url":"https://finnhub.io/api/news?id=73eb6ea9964792dd56d2fb2b2f2942337fa260c9cdd64aea611f01d6a23dcd60","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.","category":"company","datetime":1790336197,"headline":"2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds"}, {"id":142389564,"url":"https://finnhub.io/api/news?id=ab4f9e99bbbeb3352d6984d2da00ffaa897b44bbcdf67afb376dbf86253e3dd1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...","category":"company","datetime":1790295609,"headline":"DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow"}, {"id":142370918,"url":"https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...","category":"company","datetime":1790224168,"headline":"Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"}, {"id":142366064,"url":"https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...","category":"company","datetime":1790201622,"headline":"DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"}, {"id":142364255,"url":"https://finnhub.io/api/news?id=895685be22cd87859303846feda7f64760fc0297ce940d33c824aa0414d154ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.","category":"company","datetime":1790101500,"headline":"Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring"}, {"id":142310755,"url":"https://finnhub.io/api/news?id=92eed5103bf0ea374a58ca1e7b576333d065b92ab5af27bca906a641b348f8df","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.","category":"company","datetime":1789988065,"headline":"2 Nasdaq 100 Stocks for Long-Term Investors and 1 We Turn Down"}, {"id":142307394,"url":"https://finnhub.io/api/news?id=7bc174f162091d9036397952184db2de41e5e61e125e11ffded05e0f7cc529bc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- \"Wearable Biosensors Market - Global Forecast to 2036\" has been added to ResearchAndMarkets.com's offering.According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of ch","category":"company","datetime":1789981440,"headline":"Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key Players"}, {"id":142271637,"url":"https://finnhub.io/api/news?id=730ce01b8e45e7d0d0cea2dc2e8151ad596a5f7f5e6060130ea168cdd26aa9e1","image":"","source":"Benzinga","related":"DXCM","summary":"Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.","category":"company","datetime":1789735782,"headline":"Truist Securities Maintains Buy on DexCom, Raises Price Target to $102"}, {"id":142271638,"url":"https://finnhub.io/api/news?id=6ee129161211c25318ac879637ad4a449a31809f2b9f29daed78db95040e7dfb","image":"","source":"Benzinga","related":"DXCM","summary":"TD Cowen analyst Joshua Jennings reiterates DexCom (NASDAQ:DXCM) with a Buy and maintains $95 price target.","category":"company","datetime":1789728853,"headline":"TD Cowen Reiterates Buy on DexCom, Maintains $95 Price Target"}, {"id":142253117,"url":"https://finnhub.io/api/news?id=e11028fe46d2f48c6ef48e72b060b54606b0ee35c8994be445e30b364af77ec5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.","category":"company","datetime":1789727560,"headline":"2 Unpopular Stocks That Should Get More Attention and 1 We Question"}, {"id":142197315,"url":"https://finnhub.io/api/news?id=f9b690efa346ffbc94d60bb451c6e3888d4bef728ac1204db8a94505ecd775e6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.","category":"company","datetime":1789529598,"headline":"Dexcom gives CFO Jereme Sylvain expanded role"}, {"id":142141666,"url":"https://finnhub.io/api/news?id=e1cab6faa1b4651b320e6f31733d8419da2548b0a2da7354abd2eaf3d116e8db","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"SAN DIEGO, September 14, 2026--Dexcom Promotes Jereme Sylvain to Chief Operating Officer","category":"company","datetime":1789417800,"headline":"Dexcom Promotes Jereme Sylvain to Chief Operating Officer"}, {"id":142141667,"url":"https://finnhub.io/api/news?id=c8407fc472f5b8188b750160e88317d29915f29a69289864ca15585955b9537b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.","category":"company","datetime":1789411440,"headline":"Here's Why You Should Retain DexCom Stock in Your Portfolio for Now"}, {"id":142066269,"url":"https://finnhub.io/api/news?id=a9b86a2669b0dee4fa3b7a2d1d65e1fb21112612dcc3ec4f51125f9f2cd786c8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.","category":"company","datetime":1789071300,"headline":"Dexcom Appoints Glenn Boehnlein to Board of Directors"}, {"id":142061722,"url":"https://finnhub.io/api/news?id=1b09565d259ac9bfe618da32adb94625e41d949d1b28c9c53714134c2294b0d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.","category":"company","datetime":1789053664,"headline":"3 Quality Compounders with Impressive Fundamentals"}, {"id":142025511,"url":"https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"DXCM","summary":"DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...","category":"company","datetime":1788952625,"headline":"DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"}, {"id":141953963,"url":"https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.","category":"company","datetime":1788871017,"headline":"DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"}, {"id":141425987,"url":"https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...","category":"company","datetime":1788506376,"headline":"DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"}, {"id":141403938,"url":"https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.","category":"company","datetime":1788463638,"headline":"Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"}, {"id":141396046,"url":"https://finnhub.io/api/news?id=90fc089244dc8485ed1bae6ed814953047aba3ac1c4095ec57995ccba0e89f82","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.","category":"company","datetime":1788414660,"headline":"Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services"}, {"id":141364461,"url":"https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.","category":"company","datetime":1788275900,"headline":"3 Reasons DXCM Has Explosive Upside Potential"}, {"id":141364462,"url":"https://finnhub.io/api/news?id=13c97255d370689eb9f90297a0211b08089b8745c33c05d2de88651317780fa0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.","category":"company","datetime":1788269400,"headline":"Dexcom Announces Upcoming Conference Presentation"}, {"id":141364463,"url":"https://finnhub.io/api/news?id=c9b6fc6bffb3e3d7e0e29642779ed31313c55591b3bc61dab67540e17181933a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DXCM","summary":"Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.","category":"company","datetime":1788183001,"headline":"Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 29
discarded_article_count 21
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 4.6 5/110 92% 4.6
資金流 12.4 20/110 62% 12.4
市場環境 9.4 15/110 62.67% 9.4
催化劑 2 20/110 10% 2
風險管理 7.4 10/110 74% 7.4
技術信號 18.8 30/110 62.67% 18.8
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 4/50
ret_5d -0.0164
max_score 50
max_total 50
raw_total 4
vcp_bonus 0
vol_ratio 0.8401
ret_points 0
vol_points 0
range_ratio 0.7062
volat_points 0
day_range_pct 0.0173
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 4
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.6

details

atrPct 2.4341
turnoverUsdM 294.1687
liquidityPoints 0.6
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DXCM
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 82.0892

strength_details

ma_score 2
atr_score 2
rsi_score 2
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 4.9
take_profit_price 90.7463
target_multiplier 1.9
technical_strength 1.68
take_profit_percent 5.2
positionPoints 1.6
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.8682
diversificationPoints 2

Calculation audit log

基本面分析總分: 4.6/5分
資金流分析總分: 12.4/20分
市場環境分析總分: 9.4/15分
催化劑分析: 2/20分
風險管理總分: 7.4/10分
技術信號分析總分: 18.8/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 71.43
atr
atr 2.1004
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.43
cci
rule Cursor_18.24 CCI bands
level 弱勢
score 4
value -34.44
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0815
kdj
d 48.23
j 9.31
k 35.26
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 強資金流入
score 10
value 71.05
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 51663930
recentSlope 753363
previousSlope 285010
rsi
value 57.61
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 84.2862
position SAR喺價下
distancePct 2.32
previousTrend 上升
ma50
value 85.7822
macd
macd 0.1566
trend 中性偏多
signal 0.4336
histogram -0.277
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 87.0901
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.83
score 4
avgVolume 4120784
currentVolume 3409070
derived
ma20 86.9565
ma50 85.7822
prevClose 86.64
avgVolume10 4585097
avgVolume20 4120784
changePercent -0.4
avgVolumeForScore 4120784
ma_cross
ma20 86.9565
ma50 85.7822
rule Cursor_18.24 MA20/MA50 cross
cross 接近
score 6
prevMa20 87.149
prevMa50 85.5514
spreadPct 1.37
isVolumeBreakout false
bollinger
lower 83.0048
upper 90.9082
position 中間
rsi_short
value 1.79
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.83

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.434117510719666,
        "turnoverUsdM": 294.1686503,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DXCM",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 82.0892,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.9,
      "take_profit_price": 90.7463,
      "target_multiplier": 1.9,
      "technical_strength": 1.68,
      "take_profit_percent": 5.2
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.868235021439332,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 62.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 58.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 86.9565,
    "ma50": 85.7822,
    "close": 86.29,
    "prevClose": 86.64,
    "avgVolume20": 4120784,
    "volumeRatio": 0.83,
    "changePercent": -0.4
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": -0.016413997492305876,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.8401048815769694,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.706190389874816,
      "volat_points": 0,
      "day_range_pct": 0.017325298412330565,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 62.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 9.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 62.67,
        "contribution": 9.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 18.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 62.67,
        "contribution": 18.8
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 58.6,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 9.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 18.8/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 12.4,
      "市場環境": 9.4,
      "情緒分析": 4,
      "技術信號": 18.8,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 294.1686503,
          "volumePoints": 0.5,
          "revenuePoints": 0.6,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DXCM",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.04
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 724.5444967999999,
                "ma50": 714.93099846,
                "name": "QQQ",
                "close": 739.77002,
                "points": 2
              },
              "spy": {
                "ma20": 765.0634969,
                "ma50": 762.7413972399996,
                "name": "SPY",
                "close": 762.63,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.434117510719666,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142389564,
                "url": "https://finnhub.io/api/news?id=ab4f9e99bbbeb3352d6984d2da00ffaa897b44bbcdf67afb376dbf86253e3dd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...",
                "category": "company",
                "datetime": 1790295609,
                "headline": "DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow"
              },
              {
                "id": 142370918,
                "url": "https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...",
                "category": "company",
                "datetime": 1790224168,
                "headline": "Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"
              },
              {
                "id": 142366064,
                "url": "https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...",
                "category": "company",
                "datetime": 1790201622,
                "headline": "DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"
              },
              {
                "id": 142025511,
                "url": "https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "DXCM",
                "summary": "DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...",
                "category": "company",
                "datetime": 1788952625,
                "headline": "DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141953963,
                "url": "https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.",
                "category": "company",
                "datetime": 1788871017,
                "headline": "DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"
              },
              {
                "id": 141425987,
                "url": "https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...",
                "category": "company",
                "datetime": 1788506376,
                "headline": "DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"
              },
              {
                "id": 141403938,
                "url": "https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.",
                "category": "company",
                "datetime": 1788463638,
                "headline": "Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"
              },
              {
                "id": 141364461,
                "url": "https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788275900,
                "headline": "3 Reasons DXCM Has Explosive Upside Potential"
              }
            ],
            "raw_source": [
              {
                "id": 142498271,
                "url": "https://finnhub.io/api/news?id=c8a3883a0d743ae06ec3b632acdcbfbf365a4abeaa0485104c7b26b8a525f462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.",
                "category": "company",
                "datetime": 1790690760,
                "headline": "Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal"
              },
              {
                "id": 142471977,
                "url": "https://finnhub.io/api/news?id=9a9e8c90864916b48c6ae5ca4c5a7b7e7529ccc85f497dba335c6b61d6fd5ef0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion.",
                "category": "company",
                "datetime": 1790627760,
                "headline": "This Stock Could Be the Big Winner Out of Oura’s IPO"
              },
              {
                "id": 142467285,
                "url": "https://finnhub.io/api/news?id=3769358d3e460e01434eddeed80016e677e5f20103e739e42ecba5af01f9f33d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/28/Stock-market-chart--representative-image.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DXCM",
                "summary": "Market Overview\n\n\n\nStocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the",
                "category": "company",
                "datetime": 1790585196,
                "headline": "The Insider Report: The Leaders Have Taken Off"
              },
              {
                "id": 142460907,
                "url": "https://finnhub.io/api/news?id=a57368bc532321048255f0eef4d920cdc87da7fdf7b0ffdeef89f459559e6839",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.",
                "category": "company",
                "datetime": 1790578800,
                "headline": "Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets"
              },
              {
                "id": 142460906,
                "url": "https://finnhub.io/api/news?id=d7a5888e163f7e34cadd3d2f283f60b4d3498bf33975189d23da7e00b1acf7e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "MILAN, September 28, 2026--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its \"Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology\" in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28-Oct. 2. The company also announced a partnership to become the official continuous glucose monitor of Team Novo Nordisk.",
                "category": "company",
                "datetime": 1790575200,
                "headline": "Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care"
              },
              {
                "id": 142467762,
                "url": "https://finnhub.io/api/news?id=b6dca09324250ed8938c3bd363d9f85be70e0d34f6d15f85c4c20ae05dfa6950",
                "image": "",
                "source": "Benzinga",
                "related": "DXCM",
                "summary": "New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s commitment to advancing",
                "category": "company",
                "datetime": 1790565474,
                "headline": "Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries"
              },
              {
                "id": 142421217,
                "url": "https://finnhub.io/api/news?id=73eb6ea9964792dd56d2fb2b2f2942337fa260c9cdd64aea611f01d6a23dcd60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
                "category": "company",
                "datetime": 1790336197,
                "headline": "2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds"
              },
              {
                "id": 142389564,
                "url": "https://finnhub.io/api/news?id=ab4f9e99bbbeb3352d6984d2da00ffaa897b44bbcdf67afb376dbf86253e3dd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking at the chart today. Is the current US$87.47 price adequately supported by the cash the business is expected to generate over time? Over the past 5 years the stock has declined 36.0%, which puts the focus squarely on whether the cash flow story still lines up with the share price. The recent move to expand Jereme Sylvain’s remit to Chief Operating Officer as well as...",
                "category": "company",
                "datetime": 1790295609,
                "headline": "DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow"
              },
              {
                "id": 142370918,
                "url": "https://finnhub.io/api/news?id=7e80c34757dfb5e8e97506f9fb195de5bb917984d87162696be91d6a79a644bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (DXCM) just reshuffled its leadership team, with longtime finance chief Jereme Sylvain stepping into a combined EVP and Chief Operating Officer role that now includes responsibility for global operations and quality. Recent boardroom moves at DexCom have arrived at a time when the 90-day share price return of 27.79% and year-to-date gain of 31.85% point to building momentum. However, the 1-year total shareholder return of 29.97% contrasts with a weaker 3-year record and a deeper 5-year...",
                "category": "company",
                "datetime": 1790224168,
                "headline": "Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced?"
              },
              {
                "id": 142366064,
                "url": "https://finnhub.io/api/news?id=a735547d4009b8a6a2ff1c97ea29d07de4f3eb90a08524cdb3ae4c0418045a0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom (NasdaqGS:DXCM) has promoted former Chief Financial Officer Jereme Sylvain to EVP and Chief Operating Officer. Healthcare executive Glenn S. Boehnlein has joined DexCom's board of directors, adding external industry experience to governance. The leadership shift, including Sylvain's promotion and Boehnlein's board appointment, deserves weighing alongside DexCom's broader fundamentals and risks. Take a look at 3 other big wins we have identified for DexCom. For readers looking to...",
                "category": "company",
                "datetime": 1790201622,
                "headline": "DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer"
              },
              {
                "id": 142364255,
                "url": "https://finnhub.io/api/news?id=895685be22cd87859303846feda7f64760fc0297ce940d33c824aa0414d154ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.",
                "category": "company",
                "datetime": 1790101500,
                "headline": "Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring"
              },
              {
                "id": 142310755,
                "url": "https://finnhub.io/api/news?id=92eed5103bf0ea374a58ca1e7b576333d065b92ab5af27bca906a641b348f8df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.",
                "category": "company",
                "datetime": 1789988065,
                "headline": "2 Nasdaq 100 Stocks for Long-Term Investors and 1 We Turn Down"
              },
              {
                "id": 142307394,
                "url": "https://finnhub.io/api/news?id=7bc174f162091d9036397952184db2de41e5e61e125e11ffded05e0f7cc529bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Dublin, Sept. 21, 2026 (GLOBE NEWSWIRE) -- \"Wearable Biosensors Market - Global Forecast to 2036\" has been added to ResearchAndMarkets.com's offering.According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of ch",
                "category": "company",
                "datetime": 1789981440,
                "headline": "Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key Players"
              },
              {
                "id": 142271637,
                "url": "https://finnhub.io/api/news?id=730ce01b8e45e7d0d0cea2dc2e8151ad596a5f7f5e6060130ea168cdd26aa9e1",
                "image": "",
                "source": "Benzinga",
                "related": "DXCM",
                "summary": "Truist Securities  analyst Richard Newitter   maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $93 to $102.",
                "category": "company",
                "datetime": 1789735782,
                "headline": "Truist Securities Maintains Buy on DexCom, Raises Price Target to $102"
              },
              {
                "id": 142271638,
                "url": "https://finnhub.io/api/news?id=6ee129161211c25318ac879637ad4a449a31809f2b9f29daed78db95040e7dfb",
                "image": "",
                "source": "Benzinga",
                "related": "DXCM",
                "summary": "TD Cowen  analyst Joshua Jennings   reiterates DexCom (NASDAQ:DXCM) with a Buy and maintains $95 price target.",
                "category": "company",
                "datetime": 1789728853,
                "headline": "TD Cowen Reiterates Buy on DexCom, Maintains $95 Price Target"
              },
              {
                "id": 142253117,
                "url": "https://finnhub.io/api/news?id=e11028fe46d2f48c6ef48e72b060b54606b0ee35c8994be445e30b364af77ec5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1789727560,
                "headline": "2 Unpopular Stocks That Should Get More Attention and 1 We Question"
              },
              {
                "id": 142197315,
                "url": "https://finnhub.io/api/news?id=f9b690efa346ffbc94d60bb451c6e3888d4bef728ac1204db8a94505ecd775e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Sylvain will work as chief operating officer of the diabetes technology company while continuing as its CFO.",
                "category": "company",
                "datetime": 1789529598,
                "headline": "Dexcom gives CFO Jereme Sylvain expanded role"
              },
              {
                "id": 142141666,
                "url": "https://finnhub.io/api/news?id=e1cab6faa1b4651b320e6f31733d8419da2548b0a2da7354abd2eaf3d116e8db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "SAN DIEGO, September 14, 2026--Dexcom Promotes Jereme Sylvain to Chief Operating Officer",
                "category": "company",
                "datetime": 1789417800,
                "headline": "Dexcom Promotes Jereme Sylvain to Chief Operating Officer"
              },
              {
                "id": 142141667,
                "url": "https://finnhub.io/api/news?id=c8407fc472f5b8188b750160e88317d29915f29a69289864ca15585955b9537b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.",
                "category": "company",
                "datetime": 1789411440,
                "headline": "Here's Why You Should Retain DexCom Stock in Your Portfolio for Now"
              },
              {
                "id": 142066269,
                "url": "https://finnhub.io/api/news?id=a9b86a2669b0dee4fa3b7a2d1d65e1fb21112612dcc3ec4f51125f9f2cd786c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.",
                "category": "company",
                "datetime": 1789071300,
                "headline": "Dexcom Appoints Glenn Boehnlein to Board of Directors"
              },
              {
                "id": 142061722,
                "url": "https://finnhub.io/api/news?id=1b09565d259ac9bfe618da32adb94625e41d949d1b28c9c53714134c2294b0d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.",
                "category": "company",
                "datetime": 1789053664,
                "headline": "3 Quality Compounders with Impressive Fundamentals"
              },
              {
                "id": 142025511,
                "url": "https://finnhub.io/api/news?id=5e26d4769528832e8d6c467dd3c154dedeb94018b2b6266fcf8edaa9128328e5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "DXCM",
                "summary": "DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...",
                "category": "company",
                "datetime": 1788952625,
                "headline": "DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141953963,
                "url": "https://finnhub.io/api/news?id=40add1b5e5186ad6f849874bb27cb5aeef18c1510468f1b6b10b2449477c6cf9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.",
                "category": "company",
                "datetime": 1788871017,
                "headline": "DexCom Stock: Is DXCM Underperforming the Healthcare Sector?"
              },
              {
                "id": 141425987,
                "url": "https://finnhub.io/api/news?id=fc4b38d168fa041f4c4b91cf02111340a73d4f69976f0c9543c6bcb7f7a9bfbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...",
                "category": "company",
                "datetime": 1788506376,
                "headline": "DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair"
              },
              {
                "id": 141403938,
                "url": "https://finnhub.io/api/news?id=9cbd77af170c95d6ccc8f28fb46ec6d763f649ea850e92a5fadc0fb495458a36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including DexCom (NASDAQ:DXCM) and its peers.",
                "category": "company",
                "datetime": 1788463638,
                "headline": "Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks"
              },
              {
                "id": 141396046,
                "url": "https://finnhub.io/api/news?id=90fc089244dc8485ed1bae6ed814953047aba3ac1c4095ec57995ccba0e89f82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Reviewing prior stock picks is how investors turn experience into valuable feedback.  A recommendation is only a thesis until the market tests it.  Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.",
                "category": "company",
                "datetime": 1788414660,
                "headline": "Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services"
              },
              {
                "id": 141364461,
                "url": "https://finnhub.io/api/news?id=5924938bd1af69a2da1decba43d47368d52414a0182e98dcbb82df881d97656f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Over the past six months, DexCom has been a great trade, beating the S&P 500 by 11.5%. Its stock price has climbed to $91.17, representing a healthy 23.6% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
                "category": "company",
                "datetime": 1788275900,
                "headline": "3 Reasons DXCM Has Explosive Upside Potential"
              },
              {
                "id": 141364462,
                "url": "https://finnhub.io/api/news?id=13c97255d370689eb9f90297a0211b08089b8745c33c05d2de88651317780fa0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "SAN DIEGO, September 01, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.",
                "category": "company",
                "datetime": 1788269400,
                "headline": "Dexcom Announces Upcoming Conference Presentation"
              },
              {
                "id": 141364463,
                "url": "https://finnhub.io/api/news?id=c9b6fc6bffb3e3d7e0e29642779ed31313c55591b3bc61dab67540e17181933a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DXCM",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1788183001,
                "headline": "Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 29,
            "discarded_article_count": 21
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.8,
        "grade": "一般",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.5,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.5,
            "vcp_reason": "跌縮量(近10日5日)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 4092880,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 4605870,
              "avg_vol_20": 4057910,
              "avg_vol_30": 4092880,
              "range_pct_10": 0.05968246610267708,
              "range_pct_20": 0.11646772511299104,
              "range_pct_30": 0.11936493220535399,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1253371708918902,
              "dist_to_20d_high": 0.06551873510937835,
              "down_shrink_days": 5,
              "breakout_level_20d": 92.34,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5000000000000007
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.434117510719666,
              "turnoverUsdM": 294.1686503,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DXCM",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 82.0892,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.9,
            "take_profit_price": 90.7463,
            "target_multiplier": 1.9,
            "technical_strength": 1.68,
            "take_profit_percent": 5.2
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.868235021439332,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 2.1004,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.43
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -34.44
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0815
    },
    "kdj": {
      "d": 48.23,
      "j": 9.31,
      "k": 35.26,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 71.05
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 51663930,
      "recentSlope": 753363,
      "previousSlope": 285010
    },
    "rsi": 57.61,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 84.2862,
      "position": "SAR喺價下",
      "distancePct": 2.32,
      "previousTrend": "上升"
    },
    "ma50": 85.7822,
    "macd": {
      "macd": 0.15656204049709288,
      "trend": "中性偏多",
      "signal": 0.4335717191936634,
      "histogram": -0.2770096786965705
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 87.0901,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.83,
      "score": 4,
      "avgVolume": 4120784,
      "currentVolume": 3409070
    },
    "derived": {
      "ma20": 86.9565,
      "ma50": 85.7822,
      "prevClose": 86.64,
      "avgVolume10": 4585097,
      "avgVolume20": 4120784,
      "changePercent": -0.4,
      "avgVolumeForScore": 4120784
    },
    "ma_cross": {
      "ma20": 86.9565,
      "ma50": 85.7822,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 87.149,
      "prevMa50": 85.5514,
      "spreadPct": 1.37,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 83.0048,
      "upper": 90.9082,
      "position": "中間"
    },
    "rsi_short": 1.79,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.83
    }
  }
}

Raw metrics JSON

 
{
  "close": 86.29,
  "volume": 3409070,
  "changePercent": -0.4
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank provides research support only and does not provide financial advice or buy/sell recommendations.